Hatırnaz Ng, Ö. And Eşkazan, A. E. 2022. Tackling TKI resistance in AML: A commentary on "Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML." by Yamatani et al.. Translational oncology , vol.19 , 101394.

Hatırnaz Ng, Ö., & Eşkazan, A. E., (2022). Tackling TKI resistance in AML: A commentary on "Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML." by Yamatani et al.. Translational oncology , vol.19, 101394.

Hatırnaz Ng, ÖZDEN, And Ahmet Emre Eşkazan. "Tackling TKI resistance in AML: A commentary on "Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML." by Yamatani et al.," Translational oncology , vol.19, 101394, 2022

Hatırnaz Ng, ÖZDEN H. And Eşkazan, Ahmet E. . "Tackling TKI resistance in AML: A commentary on "Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML." by Yamatani et al.." Translational oncology , vol.19, pp.101394, 2022

Hatırnaz Ng, Ö. And Eşkazan, A. E. (2022) . "Tackling TKI resistance in AML: A commentary on "Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML." by Yamatani et al.." Translational oncology , vol.19, p.101394.

@article{article, author={ÖZDEN HATIRNAZ NG And author={Ahmet Emre Eşkazan}, title={Tackling TKI resistance in AML: A commentary on "Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML." by Yamatani et al.}, journal={Translational oncology}, year=2022, pages={101394} }